Abstract C1311 (5-[[2-(diethylamino) ethyl] amino]-8-hydroxyimidazo [4, 5, 1-de]-acridin-6-
onedihydrochloride trihydrate) is the lead compound from the group of imidazoacridinones …

C1311 is the most active member of a new series of rationally designed anti-cancer agents,
the imidazoacridinones, which has shown promising pre-clinical anti-tumour activity in vitro …

C1311 (5-[[2-(diethylamino) ethyl] amino]-8-hydroxyimidazo [4, 5, 1-de]-acridin-6-one-
dihydrochloride trihydrate) is the lead compound from the group of imidazoacridinones, a …

The imidazoacridinone C1311 has shown anti-tumour activity both in vitro and in vivo,
prompting its acceptance for Phase I clinical trials. A high-performance liquid …

Novel imidazoacridinone derivatives, C1310 and C1311, have been evaluated for their
potential to inhibit tumour cell growth in vitro and in vivo. A cell line panel, including seven …

C1311 is the lead compound from the imidazoacridinones, a novel group of rationally
designed anti-cancer agents. The compound is pharmaceutically formulated as a lyophilized …

Abstract ES-285. HCl [(2S, 3R)-2-aminooctadecan-3-ol hydrochloride] is a novel
investigational anticancer agent which has shown activity against various tumour cell lines …

C1311 has emerged as the lead compound from a novel group of anticancer agents, the
imidazoacridinones, and will be entering clinical trials shortly. Previous murine …

The aim of this study was to investigate the antiproliferative effects of C-1311 (Symadex), a
member of the imidazoacridinone family, in human colorectal cancer cells. In the in vitro …

PURPOSE: C-1311 is a member of the novel imidazoacridinone family of anticancer agents.
This phase 1 trial was designed to investigate the safety, tolerability and preliminary anti …